Results 151 to 160 of about 407,619 (292)

Comparison of Recent Trends in Medicare Utilization and Reimbursement for Anterior Cervical Spine Discectomy and Fusion as Compared to Cervical Disc Arthroplasty. [PDF]

Global Spine J
Davidson JC, Spears I, Alexander B, Melancon D, Lee R, McCandless M, Nehete P, Clark JC, McGuire R.   +8 more
europepmc   +1 more source

eGFR slope as predictor of mortality in heart failure patients

ESC Heart Failure, Volume 12, Issue 2, Page 1217-1226, April 2025.
Abstract Aims Heart failure (HF) leads to an imbalance between heart and kidney function, resulting in poor outcomes. However, the prognostic significance of the estimated glomerular filtration rate (eGFR) trajectory in HF patients remains unclear. We analysed electronic health records (EHRs) of real‐world HF patients, assessing eGFR trajectories and ...
Sofie Verstreken, Monika Beles, Clara L. Oeste, Ana Moya, Imke Masuy, Riet Dierckx, Ward Heggermont, Jeroen Dauw, Dries Hens, Jozef Bartunek, Marc Vanderheyden   +10 more
wiley   +1 more source

Challenges and solutions in determining urolithiasis caseloads using the digital infrastructure of a clinical data warehouse. [PDF]

PLoS One
Schönthaler M, Hempen N, Weymann M, von Bargen MF, Glienke M, Elsässer A, Behrens M, Binder H, Binder N.   +8 more
europepmc   +1 more source

Does How Much and How You Pay Matter? Evidence from the Inpatient Rehabilitation Facility Prospective Payment System [PDF]

We use the implementation of a new prospective payment system (PPS) for inpatient rehabilitation facilities (IRFs) to investigate the effect of changes in marginal and average reimbursement on costs. The results show that the IRF PPS led to a significant
Jose J. Escarce, Melinda Beeuwkes Buntin, Neeraj Sood   +2 more
core  

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

The impacts of pricing and reimbursement policies on access to cell and gene therapies across Europe. [PDF]

J Community Genet
Han Y, Andreoletti M, Minssen T, Vayena E, Ormond KE.   +4 more
europepmc   +1 more source

Policy Networks and Policy Entrepreneurship in the EU: Explaining Structural Policy Change in Pharmaceutical Innovation Incentives and Health Technology Assessment

European Policy Analysis, EarlyView.
ABSTRACT Policy process research has excelled in explaining structural policy change within national settings, but extensions and applications to the EU level have long proven challenging for scholars. Given that the EU is currently experiencing its longest period of Treaty stability since the 1980s—having evolved into a sui generis political system ...
Vassilis Karokis‐Mavrikos
wiley   +1 more source

Why will increasing medical insurance reimbursement levels not lead to over-medicalization? Evidence from China's medical insurance payment reform. [PDF]

Cost Eff Resour Alloc
Yingtan M, Yaxuan Z, Qiuming H.
europepmc   +1 more source

The Distributive Consequences of Active Welfare Policies in Europe

European Policy Analysis, EarlyView.
ABSTRACT This article examines the distributive consequences of active welfare policies in Europe by analysing tier‐specific investments in individualised employment services across four European welfare states: Denmark, Germany, the Netherlands and the United Kingdom.
Deborah Jackwerth‐Rice, Katharina Zimmermann   +1 more
wiley   +1 more source

L‐Relationship between uncertainty and average seizure frequency in clinical trials of antiseizure medications

Epilepsia, EarlyView.
Abstract Objective Antiseizure medications are approved based on clinical trials that demonstrate their efficacy as measured by reductions in seizure frequency (SF). When designing these trials, trialists must select inclusion criteria where SF can be reliably measured to maintain statistical power.
Wesley T. Kerr, Neo Kok, Katherine N. McFarlane, Advith S. Reddy, Lavanya Biju, Jacqueline A. French, Daniel M. Goldenholz   +6 more
wiley   +1 more source